Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

World renowned cardiothoracic surgeons convene at UFS
2010-03-14

World-renowned cardiothoracic surgeons from around the world will be the guests of the Department of Cardiothoracic Surgery at the University of the Free State (UFS) when a workshop for cardiothoracic surgeons is presented at the UFS Faculty of Health from Monday, 15 March to Wednesday, 17 March 2010.

The workshop is presented by the European Association of Cardiothoracic Surgery (EACTS), which focuses on development and training in Africa.

Prof. Francis Smit, Head of the UFS Department of Cardiothoracic Surgery and also member of the international cooperation committee of EACTS, says EACTS have selected the UFS, and specifically Bloemfontein, to be the site for their African Training and Education outreach. “We are extremely honoured by this after working at it for more than four years.”

Seven world-renowned cardiothoracic surgeons, including three former presidents of EACTS, will present the training courses in Bloemfontein from 15-17 March 2010. These surgeons are from the United States of America, Norway, the Netherlands, Belgium, Switzerland and Scotland.

The European Cardiovascular Technologists are sending a perfusionist as well to present a perfusion workshop on Wednesday, 17 March 2010. The last day will be devoted to advanced surgical techniques.

The programme consists of a two-day scientific course that addresses research issues. All the invited speakers are well-known and established researchers. They all have been editors/editorial staff members of major international journals.

Prof. Smit says, “The knowledge transfer to South African surgeons can be phenomenal. Young and established surgeons can also meet the experts and improve their skills in conducting and successfully publish results.”

More than a hundred participants are expected for the workshops of the first two days, of which forty from abroad. The last day would be open registration and more than 150 people are expected.

Prof. Smit says, “This is a wonderful opportunity for us to educate, stimulate and teach surgeons in South Africa. It will add to their knowledge base and introduce them to high quality research methodology that will certainly have an impact on our research output. Hopefully this will be a bi-annual event where we can teach our academic community at a very focused and high level supported by EACTS.”

Media release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
12 March 2010
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept